Literature DB >> 20191625

Multimodal treatment of patients with minor salivary gland cancer in the case of recurrent disease.

Boban M Erovic1, Christian Schopper, Johannes Pammer, Laurenz Vormittag, Amir Maleki, Markus Brunner, Gregor Heiduschka, Matthaeus Ch Grasl, Dietmar Thurnher.   

Abstract

BACKGROUND: Our aim in this study was to identify prognostic factors and the optimal therapeutic management in patients with minor salivary gland carcinomas.
METHODS: Overall and disease-free survival and overall survival after recurrence in patients with adenoidcystic carcinoma (n = 25), mucoepidermoid carcinoma (n = 8), adenocarcinoma (n = 5), carcinoma ex pleomorphic adenoma (n = 4), and others (n = 5) were correlated to clinical data.
RESULTS: Overall survival correlated to treatment modality (p = .039) and T classification (p = .003), whereas prolonged disease-free interval correlated to treatment (p < .001) and T classification (p = .009). Overall survival after recurrence correlated to treatment of recurrence (p = .006) and initial T classification (p = .02). Multivariate analysis showed that overall survival after recurrence correlated to treatment of recurrence (p = .019) and initial T classification (p = 0.019). T classification was a prognostic factor for overall survival (p = .002) and disease-free interval (p = .002).
CONCLUSIONS: The initial tumor classification is a clinical predictor for patients' overall and disease-free survival and overall survival after recurrence. Multimodal treatment significantly improves patients' overall survival.

Entities:  

Mesh:

Year:  2010        PMID: 20191625     DOI: 10.1002/hed.21312

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  7 in total

1.  Relapsing high grade mucoepidermoid carcinoma. Long-lasting complete response following reirradiation and EGFR blockade.

Authors:  D Milanovic; B Jeremic; G Kayser; H C Rischke; J Pfeiffer; A Henke
Journal:  Strahlenther Onkol       Date:  2012-04-12       Impact factor: 3.621

Review 2.  Follow-up strategies in head and neck cancer other than upper aerodigestive tract squamous cell carcinoma.

Authors:  Antoine Digonnet; Marc Hamoir; Guy Andry; Vincent Vander Poorten; Missak Haigentz; Johannes A Langendijk; Remco de Bree; Michael L Hinni; William M Mendenhall; Vinidh Paleri; Alessandra Rinaldo; Jochen A Werner; Robert P Takes; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-10-26       Impact factor: 2.503

3.  Minor salivary gland carcinoma: a review of 35 cases.

Authors:  Georg Haymerle; Sven Schneider; Luke Harris; Theresia Häupl; Christian Schopper; Johannes Pammer; Matthaeus Ch Grasl; Boban M Erovic
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-10-23       Impact factor: 2.503

4.  Nodal Metastases in Acinic Cell Carcinoma of the Parotid Gland.

Authors:  Stefan Grasl; Stefan Janik; Matthaeus C Grasl; Johannes Pammer; Michael Formanek; Ilan Weinreb; Bayardo Perez-Ordonez; Andrew Hope; Ali Hosni; John R de Almeida; Jon Irish; Ralph Gilbert; David P Goldstein; Boban M Erovic
Journal:  J Clin Med       Date:  2019-08-27       Impact factor: 4.241

Review 5.  Estimating survival after salvage surgery for recurrent salivary gland cancers: Systematic review.

Authors:  Giuditta Mannelli; Lara V Comini; Andrea Sacchetto; Roberto Santoro; Giuseppe Spinelli; Pierluigi Bonomo; Isacco Desideri; Paolo Bossi; Ester Orlandi; Giammarco Alderotti; Alessandro Franchi; Annarita Palomba; Albino Eccher; Daniele Marchioni; Riccardo Nocini; Cesare Piazza; Gabriele Molteni
Journal:  Head Neck       Date:  2022-04-20       Impact factor: 3.821

Review 6.  Polymorphous low-grade adenocarcinoma: an analysis of epidemiological studies and hints for pathologists.

Authors:  Vera Cavalcanti de Araujo; Fabricio Passador-Santos; Cecilia Turssi; Andresa Borges Soares; Ney Soares de Araujo
Journal:  Diagn Pathol       Date:  2013-01-15       Impact factor: 2.644

7.  ELMO3 - a Negative Prognostic Marker in Minor Salivary Gland Carcinoma.

Authors:  Ulana Kotowski; Lorenz Kadletz; Sven Schneider; Felicitas Oberndorfer; Boban M Erovic; Matthaeus Ch Grasl; Claudia Lill; Gregor Heiduschka
Journal:  Pathol Oncol Res       Date:  2018-10-29       Impact factor: 3.201

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.